Dr. Adam Rogers appointed chair as company advances toward key milestones following positive topline chronic cohort results ...

The goal is to test whether the chip can give people who are paralyzed the ability to use their mind to control electronic ...

NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative ...

A team of researchers at Rowan University has developed an injectable biomaterial that could significantly improve recovery ...

A breakthrough spinal implant restored movement in paralyzed rats using gentle electric pulses—offering new hope for treating spinal cord injuries in humans.

Scientists say they are already seeing ‘tantalising’ early results in an innovative trial of an implant which emits red light ...

A paralyzed United States military veteran has been implanted with the ground-breaking Neuralink brain-computer device by ...

The entrepreneurial landscape in 2025 looks different from what it used to be. Today’s leaders are reshaping how we think ...

The department has pledged it will meet an end-of-the-year deadline early for halting spinal cord injury research that used ...

Detailed price information for Nervgen Pharma Corp (NGEN-X) from The Globe and Mail including charting and trades.

A+ A- AFP Tokyo: A stem cell treatment helped improve the motor function of two out of four patients with a spinal cord injury in the first clinical study of its kind, Japanese scientists said.